Silence is the lack of audible sound or presence of sounds of very low intensity.
Recommended Dosing. Ventavis is intended to be inhaled using the I-nebÂ® AAD Â® System. The first inhaled dose should be 2.5 mcg (as delivered at the mouthpiece). If this dose is well tolerated, dosing should be increased to 5.0 mcg and maintained at that dose; otherwise maintain the dose at 2.5 mcg.
In clinical studies, common adverse reactions due to Ventavis included vasodilation (flushing), cough, headache, trismus, and insomnia. On physical examination, the patient was observed to have trismus, lateral displacement of the left oral commissure, and extension of the mass into the oral cavity.